Literature DB >> 15049016

Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.

Riccardo Haupt1, Vasanta Nanduri, Maria Grazia Calevo, Cecilia Bernstrand, Jorge L Braier, Valerie Broadbent, Guadalupe Rey, Kenneth L McClain, Gritta Janka-Schaub, R Maarten Egeler.   

Abstract

BACKGROUND: Permanent consequences (PC) are often described among subjects with Langerhans cell histiocytosis (LCH) but data on the real incidence are scarce. Within the Histiocyte Society (HS), and in order to design a definitive late effects study, a retrospective survey was organized to describe the prevalence of PC among long-term survivors of LCH.
METHODS: Nine institutions contributed with their LCH patients having a minimum follow-up of 3 years. Information was collected on their disease-history, and on type and date of onset of any PC. Because of the retrospective type of this study, it was accepted that each institution might have used different criteria to assess PC.
RESULTS: One hundred eighty-two subjects were registered and in 95 (52%) at least 1 PC was reported. For some specific PC (e.g., anterior pituitary dysfunction) information was too scarce to provide reliable data. PC were more frequent among subjects with multisystem (MS) disease (71%), compared to those with single system (SS) disease (24%); P < 0.0001. The most frequently reported PC were diabetes insipidus (DI) (24%) orthopedic abnormalities (20%), hearing loss (13%), and neurological consequences (11.0%). Analysis of cumulative risk showed that some types of PC may become manifest more than 10 years from diagnosis.
CONCLUSIONS: This survey on selected cases of LCH survivors has confirmed that late sequels are frequent, and that they are even more common among those with MS LCH. Our findings highlight the need for long-term and patient-oriented follow-up in children with LCH. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15049016     DOI: 10.1002/pbc.20021

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  39 in total

1.  Genital ulceration in a 4 year old--a case of safeguarding? From social services to pathology...

Authors:  Emma Roche; Nikila Pandya; Lamios Munthali; Ayad Atra
Journal:  BMJ Case Rep       Date:  2012-06-21

2.  Differentiating skin-limited and multisystem Langerhans cell histiocytosis.

Authors:  Stephen J Simko; Benjamin Garmezy; Harshal Abhyankar; Philip J Lupo; Rikhia Chakraborty; Karen Phaik Har Lim; Albert Shih; M John Hicks; Teresa S Wright; Moise L Levy; Kenneth L McClain; Carl E Allen
Journal:  J Pediatr       Date:  2014-10-21       Impact factor: 4.406

Review 3.  Pediatric lymphomas and histiocytic disorders of childhood.

Authors:  Carl E Allen; Kara M Kelly; Catherine M Bollard
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

4.  How I treat Langerhans cell histiocytosis.

Authors:  Carl E Allen; Stephan Ladisch; Kenneth L McClain
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

5.  Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.

Authors:  Olive S Eckstein; Johannes Visser; Carlos Rodriguez-Galindo; Carl E Allen
Journal:  Blood       Date:  2019-02-04       Impact factor: 22.113

Review 6.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

7.  The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics.

Authors:  Erin C Peckham-Gregory; Kenneth L McClain; Carl E Allen; Michael E Scheurer; Philip J Lupo
Journal:  Ann Epidemiol       Date:  2018-04-17       Impact factor: 3.797

8.  Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems.

Authors:  Shinsaku Imashuku; Naoko Kinugawa; Akinobu Matsuzaki; Toshiyuki Kitoh; Kentaro Ohki; Yoko Shioda; Yukiko Tsunematsu; Toshihiko Imamura; Akira Morimoto
Journal:  Int J Hematol       Date:  2009-09-25       Impact factor: 2.490

9.  Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group.

Authors:  Akira Morimoto; Chihiro Shimazaki; Satoshi Takahashi; Kouhei Yoshikawa; Ryosei Nishimura; Hisashi Wakita; Yutaka Kobayashi; Hirokazu Kanegane; Arinobu Tojo; Toshihiko Imamura; Shinsaku Imashuku
Journal:  Int J Hematol       Date:  2012-12-16       Impact factor: 2.490

10.  Langerhan's cell histiocytosis: A single institutional experience.

Authors:  Tejinder Singh; C T Satheesh; L Appaji; B S Aruna Kumari; H S Mamatha; G V Giri; Clementina Rama Rao
Journal:  Indian J Med Paediatr Oncol       Date:  2010-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.